right from the beginning, which is now more than fifty years ago, bruker has been driven by a single idea: to provide the best technological solution for each analytical task. today, worldwide, more than 6,500 employees in over 90 locations on all continents are focusing their efforts on this permanent challenge. bruker systems cover a broad spectrum of applications in all fields of research and development and are used in all industrial production processes for the purpose of ensuring quality and process reliability. bruker continues to build upon its extensive range of products and solutions, expand its broad base of installed systems and maintain a strong reputation amongst its customers. as one of the world's leading analytical instrumentation companies, bruker remains focused on developing state-of-the-art technologies and innovative solutions for today’s ever complex analytical questions. bruker - innovation with integrity. bruker corporation company pages bruker axs: https://www
Company profile
Ticker
BRKR
Exchange
Website
CEO
Frank Laukien
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BRUKER BIOSCIENCES CORP, BRUKER DALTONICS INC
SEC CIK
Corporate docs
Subsidiaries
Acquifer Imaging GmbH • Acuity Spatial Genomics, Inc. • Agapetus GmbH • Alicona Imaging GmbH • Anasys Instruments Corporation • Biognosys, AG • Biognosys, Inc. • Bruker (Beijing) Scientific Technology Co., Ltd. • Bruker (Malaysia) SDN. BHD. • Bruker Arabia Limited ...
IRS number
43110160
BRKR stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
15 May 24
10-Q
2024 Q1
Quarterly report
10 May 24
8-K
Bruker Reports First Quarter 2024 Financial Results
2 May 24
8-K
Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech
2 May 24
8-K
Bruker to Acquire the NanoString Business in an Asset Deal
22 Apr 24
DEFA14A
Additional proxy soliciting materials
19 Apr 24
DEF 14A
Definitive proxy
19 Apr 24
8-K
Entry into a Material Definitive Agreement
2 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Bruker Reports Fourth Quarter and Full Year 2023 Financial Results
13 Feb 24
Transcripts
BRKR
Earnings call transcript
2024 Q1
2 May 24
BRKR
Earnings call transcript
2023 Q4
13 Feb 24
BRKR
Earnings call transcript
2023 Q3
2 Nov 23
BRKR
Earnings call transcript
2023 Q2
3 Aug 23
BRKR
Earnings call transcript
2023 Q2
3 Aug 23
BRKR
Earnings call transcript
2023 Q1
4 May 23
BRKR
Earnings call transcript
2023 Q1
4 May 23
BRKR
Earnings call transcript
2022 Q4
9 Feb 23
BRKR
Earnings call transcript
2022 Q3
3 Nov 22
BRKR
Earnings call transcript
2022 Q2
4 Aug 22
Latest ownership filings
4
FRANK H LAUKIEN
12 Mar 24
4
Hermann Fritz Requardt
6 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
4
Falko Busse
1 Mar 24
144
Notice of proposed sale of securities
28 Feb 24
4
Burkhard Prause
26 Feb 24
144
Notice of proposed sale of securities
22 Feb 24
SC 13G/A
T. Rowe Price Investment Management, Inc.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
9 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 343.30 mm | 343.30 mm | 343.30 mm | 343.30 mm | 343.30 mm | 343.30 mm |
Cash burn (monthly) | 49.43 mm | 21.51 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 78.51 mm | 34.16 mm | n/a | n/a | n/a | n/a |
Cash remaining | 264.79 mm | 309.14 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 5.4 | 14.4 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
49.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 262 |
Opened positions | 43 |
Closed positions | 119 |
Increased positions | 85 |
Reduced positions | 103 |
13F shares | Current |
---|---|
Total value | 4.95 tn |
Total shares | 71.47 mm |
Total puts | 10.30 k |
Total calls | 21.30 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 9.90 mm | $727.22 bn |
FMR | 9.43 mm | $693.08 bn |
Pallas Capital Advisors | 8.43 mm | $619.10 bn |
Massachusetts Financial Services | 8.08 mm | $593.72 bn |
RTW Investments | 3.34 mm | $245.72 bn |
STT State Street | 3.16 mm | $232.00 bn |
IVZ Invesco | 1.98 mm | $145.82 bn |
Fuller & Thaler Asset Management | 1.89 mm | $138.76 bn |
GS Goldman Sachs | 1.78 mm | $131.06 bn |
TD Asset Management | 1.66 mm | $122.33 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Feb 24 | Falko Busse | Common Stock | Sell | Dispose S | No | No | 84.48 | 1,500 | 126.72 k | 32,859 |
28 Feb 24 | Falko Busse | Common Stock | Sell | Dispose S | No | No | 84.97 | 12,770 | 1.09 mm | 34,359 |
28 Feb 24 | Falko Busse | Common Stock | Sell | Dispose S | No | No | 86.06 | 13,852 | 1.19 mm | 47,129 |
28 Feb 24 | Falko Busse | Common Stock | Option exercise | Acquire M | No | No | 41.95 | 4,641 | 194.69 k | 60,981 |
28 Feb 24 | Falko Busse | Common Stock | Option exercise | Acquire M | No | No | 34.02 | 4,384 | 149.14 k | 56,340 |
28 Feb 24 | Falko Busse | Common Stock | Option exercise | Acquire M | No | No | 22.19 | 7,097 | 157.48 k | 51,956 |
28 Feb 24 | Falko Busse | Common Stock | Option exercise | Acquire M | No | No | 19.82 | 12,000 | 237.84 k | 44,859 |
28 Feb 24 | Falko Busse | Stock Option (Right to Purchase) Common Stock | Option exercise | Dispose M | No | No | 41.95 | 4,641 | 194.69 k | 0 |
28 Feb 24 | Falko Busse | Stock Option (Right to Purchase) Common Stock | Option exercise | Dispose M | No | No | 34.02 | 4,384 | 149.14 k | 0 |
28 Feb 24 | Falko Busse | Stock Option (Right to Purchase) Common Stock | Option exercise | Dispose M | No | No | 22.19 | 7,097 | 157.48 k | 0 |
News
German Federal Patent Court Invalidates Patent Asserted By 10x Genomics, Delivering Legal Win To NanoString, Now A Bruker Business, Will Seek An End To The Injunction Impacting Sales Of CosMx SMI Products In Germany
7 May 24
Last Week's Worst-Performing Stocks: Are These 15 Large-Cap Stocks In Your Portfolio? (April 28-May 4, 2024)
5 May 24
12 Health Care Stocks Moving In Thursday's Intraday Session
2 May 24
Bruker Updates 2024 Outlook: Now Sees Revenue Of $3.29B-$3.35B (Prior $3.23B-$3.29B) Vs. $3.282B Est.; Sees Adjusted EPS Of $2.79 To $2.84 (Prior $2.71-$2.76) Vs. $2.71 Est.
2 May 24
Bruker Q1 2024 Adj EPS $0.53 Beats $0.46 Estimate, Sales $721.700M Miss $729.879M Estimate
2 May 24
Press releases
Access Reminder for Bruker Investor Webinar on May 17, 2024
16 May 24
Bruker Announces Quarterly Dividend
15 May 24
Bruker Corporation to Host Investor Webinar on May 17, 2024
9 May 24
German Federal Patent Court Invalidates Patent Asserted By 10x Genomics, Delivering Legal Win to NanoString and Bruker
7 May 24
Bruker Completes Asset Acquisition of NanoString Business
6 May 24